In an accompanying paper (1) human growth hormo.ne (HGH) was reported to have stimulated the rate of linear growth, produced retention of nitrogen, phosphorus, magnesium, calcium, sodium and potassium, and perhaps increased the rate of fat mobilization in ten human subjects. This paper describes the response of blood and urinary levels of fat and carbohydrate intermediary metabolites in seven of these and in one infant with hyperinsulinism.1 Some effects of HGH on carbohydrate and fat metabolism have already been published. Raben and Hollenberg (2) observed a prompt and significant rise in plasma free fatty acids (FFA). Beck, McGarry, Dyrenfurth and Venning (3) reported alterations in glucose tolerance in four of six patients and Ikkos, Luft and Gemzell (4) in two of two patients. Ikkos and associates also observed elevations in ketone bodies in three of four patients. The data to be reported in general confirm these observations and include the simultaneous measurements of blood and urinary glucose, lactate, pyruvate, citrate, a-ketoglutarate, free fatty acids and ketones during short and longterm HGH therapy.
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MATERIAL AND METHODS
The clinical features of the patients studied are reported elsewhere (1) . The subjects include 5 patients with hypopituitarism, 1 patient with obesity on an 800 calorie diet and 1 patient with proven hyperinsulinism (5) . All patients were studied under constant conditions.
Blood levels of carbohydrate and fat intermediary metabolites were measured 4, 8 and 24 hours after injections of 1.0 to 10.0 mg of acid-soluble HGH (Raben).2 HGH was administered as a single intramuscular injection at 6 a.m. (or beginning of "metabolic day") daily for 2 to 36 days.
The methods for measurement of blood and urinary glucose, lactic, pyruvic, a-ketoglutaric and citric acids, acetone and total ketones, and inorganic phosphorus have been reported previously (6) . In addition, plasma FFA were measured by the method of Davis (7) as modified by Gordon and Cherkes (8) . Balance studies were conducted according to the method of Reifenstein, Albright and Wells (9) . RESULTS HGH (1) produced a decrease in blood urea nitrogen (BUN) and urinary nitrogen in 24 to 48 hours which was not apparent within the first four hours after injection. With constant daily HGH injections, nitrogen retention increased for 3 to 5 days, was maximal for 2 weeks, and then decreased to low levels in the fourth and fifth weeks of treatment. If HGH were discontinued for 12 days and then resumed, nitrogen retention was again marked. Other constituents of protoplasm were retained in the relative concentrations characteristic of most tissues.
Because of the multiphasic nature of the nitrogen response to HGH the measurements of intermediary metabolites have been separated as follows: the early phase (4 hours to 3 days), as nitrogen retention is developing; the second phase (3 to 15 days) during sustained maximal nitrogen Tables I and II) . Levels were elevated 24 hours after HGH in four of five subjects. Concentrations fell below control in all patients upon discontinuing HGH (Tables I and  II) during this phase. 3. Twenty-four hour urinary citrate, acetone and total ketones. Control urinary excretion of citric acid in the five patients with hypopituitarism was 283 mg per 24 hours, a level which is significantly less (p < 0.001) than normal (mean of normal subjects on constant diet was 480 mg; SE 28 mg). Daily urinary acetone and ketone levels were within normal limits during the con- (Table I1) . Once elevated, FFA concentrations generally remained above control during the first two weeks of therapy ( Figure 2 , Table II). 2. Serum and urinary citric acid. During the first two weeks of daily HGH treatment, fasting serum and/or urinary citrate rose in five patients (B.D., Figure 1 ; M.C., Figure 2 ; P.H., Table II ; M.A., Table IV ; and S.M., Table V 3-day pools in Figure 1 (Figure 2 ) and increased -in the patient with obesity (B.D., Figure 1 ). There was no significant change on the twelfth day of treatment in (Figure 1 ).
III. The third phase (15 to 36 days)
By the end of the fourth week, daily administration of HGH in the hypopituitary patients resulted in waning nitrogen retention (1) t Postcontrol period with no treatment is divided into the first 6 days (a) and the second 6 days (b) for ketone values. No significant difference in other urinary metabolites was observed between the first and second 6 day postcontrol periods. and 2). In B.D., waning nitrogen retention was accompanied by a decline in plasma FFA and blood a-ketoglutaric acid (0.22 mg per 100 ml on Day 45 of study). Urinary citrate and ketones were at or below control in B.D. during the fifth week of treatment.
During the third and fourth weeks of therapy, fasting concentrations of blood glucose were below control levels in S.M. (Table V) and M.C. (Figure 2 ) and were falling toward control levels in B.D. (Figure 1 ). Fasting concentrations of blood pyruvate were increased (Figures 1, 2 and 3) while those of lactate were decreased ( Figures  2 and 3 and Tables IV and V) in fotur patients so studied.
Decreased glucose tolerance was observed in the three patients with hypopituitarism. Data from M.C. are shown in Figure 3 When HGH was discontinued in the patients wtith hypopituitarism, urinary citrate and ketones fell to or below control ( Figure 2 and Table V) . DISCUSSION Human growth hormone in man produces consistent changes in serum and urinary citrate and ketones, plasma free fatty acids and glucose tolerance. Elevations in plasma FFA and serum anid urinary citrate generally preceded detectable changes in nitrogen metabolismii. As suggested by studies in small animals (11) these changes may reflect primary fat mobilization which would increase the supply of two-carbon fragments for subsequent disposal via the tricarboxylic acid cycle and thereby provide energy and substrate for subsequent protein synthesis. It is of special interest that B.D., an obese patient who was mobilizing fat due to caloric restriction, demonstrated similar elevations in plasma FFA and serum and urinary citrate prior to HGH. The nitrogen balance data ( 1 ) suggest a one to three day delay in establishment of maximal nitrogen retention and a waning of such maximal retention after three weeks' continuous treatment. Changes in levels of blood and urinary metabolites showed similar time relations. Thus it appears that the early metabolic response to HGH may not be identical with the response to more prolonged administration of the hormone. The relation of these changes to rate and magnitude of changes in various pathways of cellular intermediary metabolism is uncertain at present.
SUMMARY
Administration of human growth hormone (Raben) to five patients with hypopituitarism, one with hyperinsulinism, and one with obesity produced alterations in blood levels of carbohydrate and fat metabolites which preceded marked detectable changes in protein metabolism by approximately 24 hours. There was a prompt rise in plasma free fatty acids and blood and urinary citrate and ketones.
Continued daily doses of human growth hormone produced marked nitrogen retention, glucose intolerance, a sustained rise in plasma free fatty acids and serum and urinary citrate, elevations in blood pyruvate and a decrease in blood lactate. Administration of human growth hormone for more than two to three weeks resulted in gradual return of nitrogen excretion and blood and urinary metabolites toward control levels but continued glucose intolerance.
